AUPH Q4 2021 Earnings — Aurinia Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

AUPHAurinia Pharmaceuticals Inc.

$2B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$23M-53.2% YoY

Gross Profit

$23M97.9% margin

Operating Income

-$33M-139.7% margin

Net Income

-$33M-142.4% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+59.6%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$543M

Total Liabilities

$64M

Stockholders' Equity

$479M

Cash & Equivalents

$232M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$23M	$50M	-53.2%
Gross Profit	$23M	$50M	-54.2%
Operating Income	-$33M	-$8M	-306.2%
Net Income	-$33M	-$8M	-312.7%

Revenue Segments

Product

$23M100%

License

$29,0000%